Thyroid cancer ranges from well-differentiated lesions with an excellent prognosis to anaplastic carcinoma, which is almost uniformly fatal. Thus, methods to assess the behavior of thyroid malignancies are necessary to arrive at appropriate treatment decisions.
Methods
We discuss the factors that affect the prognosis of patients with well-differentiated thyroid malignancies, including papillary, follicular, Hürthle cell, and medullary thyroid carcinomas. We also review the presentation, therapy, and outcome of patients seen at our center over a span of 50 years. These data have identified those prognostic factors that are predictive of survival and recurrence in differentiated thyroid cancer.
Results
Several classifications with different variables have been developed to define risk-group categories. Three widely used systems, in addition to the TNM staging system, include AGES, AMES, and MACIS.
Conclusions
A better understanding of independently important prognostic variables will result in improved patient care and treatment.
References
1.
LandisS.H., MurrayT., BoldenS.Cancer statistics, 1999. CA Cancer J Clin.1999; 49: 8–31.
2.
FlemingI.D., CooperJ.S., HensonD.E., eds. AJCC Cancer Staging Manual.5th ed. American Joint Committee on Cancer. Philadelphia, Pa: Lippincott-Raven; 1997.
3.
HayI.D., BergstralhE.J., GoellnerJ.R.Factors influencing prognosis and outcome in differentiated thyroid carcinoma. Head and Neck Cancer. Vol III. 1993: 889–894.
4.
GillilandF.D., HuntW.C., MorrisD.M.Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program, 1973–1991. Cancer.1997; 79: 564–573.
5.
HundahlS.A., FlemingI.D., FremgenA.M.A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer.1998; 83: 2638–2648.
6.
CadyB.Staging in thyroid carcinoma. Cancer.1998; 83: 844–847.
7.
ByarD.P., GreenS.B., DorP.A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer.1979; 15: 1033–1041.
8.
CadyB.Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark, or risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg.1997; 174: 462–468.
9.
ShahaA.R., LoreeT.R., ShahJ.P.Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery.1995; 118: 1131–1138.
10.
ShermanS.I., BrierleyJ.D., SperlingM.Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer.1998; 83: 1012–1021.
11.
HayI.D., GrantC.S., TaylorW.F.Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery.1987; 102: 1088–1095.
12.
MazzaferriE.L., JhiangS.M.Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med.1994; 97: 418–428.
13.
HayI.D., BergstralhE.J., GoellnerJ.R.Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system is a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery.1993; 114: 1050–1058.
14.
CadyB., RossiR.An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery.1988; 104: 947–953.
15.
CohnK.H., BackdahlM., ForsslundG.Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy. Surgery.1984; 96: 957–971.
16.
HayI.D., BergstralhE.J., GrantC.S.Nuclear DNA content in papillary thyroid carcinoma: relationship to patient age and other conventional prognostic factors. Proc 63rd Annu Meet Am Thyroid Assn.1988: T52.
17.
SipersteinA.E., ZengQ.H., GumE.T.Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness. World J Surg.1988; 12: 528–533.
18.
ClarkO.H.Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg.1982; 196: 361–370.
19.
LennquistS.Surgical strategy in thyroid carcinoma: a clinical review. Acta Chir Scand.1986; 152: 321–338. Review.
20.
FaginJ.A., MatsuoK., KarmakerA.High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest.1993; 91: 179–184.
21.
DuhQ.Y., GumE.T., GerendP.L.Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery.1985; 98: 1000–1007.
22.
LarsenP.R., DaviesT.F., HayI.D.The thyroid gland. In: WilsonJ.D., FosterD.W., KronenbergH.M., eds. Williams Textbook of Endocrinology.9th ed.Philadelphia, Pa: WB Saunders; 1998: 389–515.
23.
HayI.D.Papillary thyroid carcinoma. Endocrinol Metab Clin North Am.1990; 19: 545–576.
24.
PasiekaJ.L., ZedeniusJ., AuerG.Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery.1992; 112: 1154–1160.
25.
GrantC.S., HayI.D.Staging and prognosis in differentiated thyroid carcinoma. Prob Gen Surg.1997; 14: 34–43.
26.
BrierleyJ.D., PanzarellaT., TsangR.W.A comparison of different staging systems predictability of patient outcome: thyroid carcinoma as an example. Cancer.1997; 79: 2414–2423. Review.
27.
LearoydD.L., MessinaM., ZedeniusJ.RET-PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J Clin Endocrinol Metab.1998; 83: 3631–3635.
28.
SuggS.L., ZhengL., RosenI.B.Ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?J Clin Endocrinol Metab.1996; 81: 3360–3365.
29.
NikiforovY.E., RowlandJ.M., BoveK.E.Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res.1997; 57: 1690–1694.
30.
CettaF., GoriM., RaffaelliN.Comment on clinical and prognostic relevance of Ret-PTC activation in patients with papillary thyroid carcinoma. J Clin Endocrinol Metab.1999; 84: 2257–2258.
31.
SmithS.A., HayI.D., GoellnerJ.R.Mortality from papillary thyroid carcinoma: a case-control study of 56 lethal cases. Cancer.1988; 62: 1381–1388.
32.
SturgisC.D., CarawayN.P., JohnstonD.A.Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer.1999; 87: 155–160.
33.
DonghiR., SozziG., PierottiM.A.The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). Oncogene.1989; 4: 521–523.
34.
GerasimovG., BronsteinM., TroshinaK.Nuclear p53 immunoreactivity in papillary thyroid cancers is associated with two established indicators of poor prognosis. Exp Mol Pathol.1995; 62: 52–62.
BrennanM.D., BergstralhE.J., van HeerdenJ.A.Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc.1991; 66: 11–22.
37.
van HeerdenJ.A., HayI.D., GoellnerJ.R.Follicular thyroid carcinoma with capsular invasion alone: a non-threatening malignancy. Surgery.1992; 112: 1130–1136.
38.
SandersL.E., CadyB.Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg.1998; 133: 419–425.
39.
WatsonR.G., BrennanM.D., GoellnerJ.R.Invasive Hürthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc.1984; 59: 851–855.
40.
RyanJ.J., HayI.D., GrantC.S.Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid. World J Surg.1988; 12: 482–487.
41.
EmerickG.T., DuhQ.Y., SipersteinA.E.Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer.1993; 72: 3287–3295.
42.
HayI.D.Cytometric DNA ploidy analysis in thyroid cancer. Diag Oncol.1991; 1: 181–188.
43.
HayI.D., RyanJ.J., GrantC.S.Prognostic significance of nondiploid DNA determined by flow cytometry in sporadic and familial medullary thyroid carcinoma. Surgery.1990; 108: 972–980.
44.
PykeC.M., HayI.D., GoellnerJ.R.Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma. Surgery.1991; 110: 964–971.
45.
GharibH., McConaheyW.M., TiegsR.D.Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc.1992; 67: 934–940.
46.
BrierleyJ., TsangR., SimpsonW.J.Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid.1996; 6: 305–310.
47.
TisellL.E., DilleyW.G., WellsS.A.Jr. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery.1996; 119: 34–39.
48.
GoodfellowP.J., WellsS.A.RET gene and its implications for cancer. J Natl Cancer Inst.1995; 87: 1515–1523. Review.
49.
BergholmU., AdamiH.O., BergstromR.Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors: the Swedish MTC Study Group. Acta Chir Scand.1990; 156: 37–46.
50.
BergholmU., BergstromR., EkbomA.Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer.1997; 79: 132–138.
51.
BergholmU., AdamiH.O., AuerG.Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. Cancer.1989; 64: 135–142.
52.
ModiglianiE., CohenR., CamposJ.M.Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'Etude des Tumeurs a Calcitonine. Clin Endocrinol.1998; 48: 265–273.
53.
GrebeS.K.G., HayI.D.The role of surgery in the management of differentiated thyroid cancer. J Endocrinol Invest.1997; 20: 32–35. Review.
54.
ShahaA.R., ShahJ.P., LoreeT.R.Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol.1997; 4: 328–333.
55.
HayI.D., GrantC.S., BergstralhE.J.Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?Surgery.1998: 124: 958–966.
56.
MaxonHR3rd, EnglaroE.E., ThomasS.R.Radioiodine-131 therapy for well-differentiated thyroid cancer: a quantitative radiation dosimetric approach. Outcome and validation in 85 patients. J Nucl Med.1992; 33: 1132–1136.
57.
SchlumbergerM., HayI.D.Use of radioactive iodine in patients with papillary and follicular thyroid cancer: towards a selective approach. J Clin Endocrinol Metab.1998; 83: 4201–4203.
58.
WartofskyL., ed. Thyroid Cancer: A Comprehensive Guide to Clinical Management.Totowa, NJ: Humana Press; 2000.
59.
MazzaferriE.L.Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol.1987; 14: 315–332. Review.
